These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32666765)

  • 1. Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities.
    Georgiev PG; Sapunarova KG; Goranova-Marinova VS; Goranov SE
    Folia Med (Plovdiv); 2020 Jun; 62(2):265-270. PubMed ID: 32666765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years.
    Musallam KM; Barella S; Origa R; Ferrero GB; Lisi R; Pasanisi A; Longo F; Gianesin B; Forni GL;
    Blood Cells Mol Dis; 2024 Jul; 107():102859. PubMed ID: 38820707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
    Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
    Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal MRI and Ferritin Monitoring of Iron Overload in Chronically Transfused and Chelated Children With Sickle Cell Anemia and Thalassemia Major.
    Aubart M; Ou P; Elie C; Canniffe C; Kutty S; Delos V; Graffigne C; de Montalembert M; Brousse V
    J Pediatr Hematol Oncol; 2016 Oct; 38(7):497-502. PubMed ID: 27548334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine.
    Pepe A; Meloni A; Pistoia L; Cuccia L; Gamberini MR; Lisi R; D'Ascola DG; Rosso R; Allò M; Spasiano A; Restaino G; Righi R; Mangione M; Positano V; Ricchi P
    Br J Haematol; 2018 Dec; 183(5):783-795. PubMed ID: 30334574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
    Gomber S; Jain P; Sharma S; Narang M
    Indian Pediatr; 2016 Mar; 53(3):207-10. PubMed ID: 27029681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.
    Kolnagou A; Natsiopoulos K; Kleanthous M; Ioannou A; Kontoghiorghes GJ
    Toxicol Mech Methods; 2013 Jan; 23(1):48-56. PubMed ID: 22943064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?
    Forni GL; Kattamis A; Kuo KHM; Maggio A; Sheth S; Taher AT; Viprakasit V
    Pediatr Blood Cancer; 2024 Aug; 71(8):e31035. PubMed ID: 38753107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.
    DivakarJose RR; Delhikumar CG; Ram Kumar G
    Indian J Pediatr; 2021 Apr; 88(4):330-335. PubMed ID: 32661609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
    Waheed N; Ali S; Butt MA
    J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging.
    Wahidiyat PA; Liauw F; Sekarsari D; Putriasih SA; Berdoukas V; Pennell DJ
    Hematology; 2017 Sep; 22(8):501-507. PubMed ID: 28218005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
    Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutathione S-transferase gene polymorphism: Relation to cardiac iron overload in Egyptian patients with Beta Thalassemia Major.
    Mokhtar GM; Sherif EM; Habeeb NM; Abdelmaksoud AA; El-Ghoroury EA; Ibrahim AS; Hamed EM
    Hematology; 2016 Jan; 21(1):46-53. PubMed ID: 26288192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior.
    Ansari S; Azarkeivan A; Miri-Aliabad G; Yousefian S; Rostami T
    Caspian J Intern Med; 2017; 8(3):159-164. PubMed ID: 28932366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.